FDA Approves First Oral Agent For Anemia in Kidney Dialysis Patients FDA Approves First Oral Agent For Anemia in Kidney Dialysis Patients
The US Food and Drug Administration has approved daprodustat as oral treatment for anemia in patients with chronic kidney disease and on dialysis, but not for patients who are not on dialysis.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Nephrology News Alert Source Type: news
More News: Anemia | Chronic Kidney Disease | Dialysis | Food and Drug Administration (FDA) | Intensive Care | Urology & Nephrology